Inovio Pharmaceuticals Securities Class Action Notice Issued
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy INO?
Source: PRnewswire
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, that they must apply to be lead plaintiff by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of its INO-3107 Biologics License Application, resulting in investor losses once the truth was revealed.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its successful track record and resources in this field.
- Investor Guidance: Investors are advised to select law firms with proven success records to ensure effective legal representation in class actions, avoiding those that merely act as intermediaries without substantial litigation experience.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.580
Low
3.00
Averages
7.33
High
13.00
Current: 1.580
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovio Pharmaceuticals Securities Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, that they must apply to be lead plaintiff by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of its INO-3107 Biologics License Application, resulting in investor losses once the truth was revealed.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its successful track record and resources in this field.
- Investor Guidance: Investors are advised to select law firms with proven success records to ensure effective legal representation in class actions, avoiding those that merely act as intermediaries without substantial litigation experience.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging investors to file lead plaintiff motions by the specified deadlines to protect their rights.
- BlackRock TCP Details: The lawsuit alleges that from November 2024 to January 2026, BlackRock failed to timely and appropriately value its investments, leading to understated unrealized losses and an overstated net asset value, which misled investors about the company's financial health.
- Oracle Lawsuit Impact: The class action against Oracle, covering June to December 2025, claims that its AI infrastructure strategy would result in significant capital expenditure increases without corresponding revenue growth, posing serious risks to the company's debt and credit rating.
- Paysafe and Inovio Situations: Paysafe's lawsuit highlights its significant exposure to a high-risk client, potentially harming revenue growth, while Inovio faces challenges in submitting a critical FDA application due to manufacturing deficiencies, jeopardizing its market prospects.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026.
- False Statements Allegation: The complaint alleges that Inovio made false and misleading statements regarding manufacturing deficiencies in its CELLECTRA device and indicated that filing for the INO-3107 BLA by 2H 2024 was unlikely, which has led to significant investor losses.
- FDA Review Issues: Inovio failed to provide sufficient evidence supporting an FDA priority review or accelerated approval for its BLA, rendering its public statements throughout the class period false and materially misleading, which negatively impacted investor confidence and stock price.
- Legal Consequences: Following the revelation of the truth about Inovio, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit for recovery, highlighting the significant legal risks that may impact the company's future operations.
See More
Faruqi & Faruqi Investigates Inovio Investor Losses
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Inovio Pharmaceuticals, focusing on investors who purchased securities between October 10, 2023, and December 26, 2025, to assess potential legal claims against the company.
- Investor Rights Reminder: The firm reminds investors that April 7, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Channels: Investors who have suffered losses are encouraged to contact Faruqi & Faruqi partner Josh Wilson directly, with multiple contact numbers provided for ease of consultation and discussion of legal options.
- Class Action Context: This investigation is linked to an existing federal securities class action against Inovio, indicating potential legal risks for the company that investors should closely monitor for implications on their investments.
See More
Inovio Pharmaceuticals Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose manufacturing deficiencies in its CELLECTRA device, which overstated the prospects of its INO-3107 Biologics License Application, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise in this field.
- How to Participate: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel, especially since the class has not yet been certified, requiring careful consideration of legal representation.
See More
Inovio Pharmaceuticals Class Action Reminder for Investors
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that April 7, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, indicating potential investor losses.
- Financial Impact: On August 8, 2024, Inovio's second quarter financial results revealed a delay in submitting the BLA to the FDA due to manufacturing issues, causing the stock price to drop 3.1% to $8.44 per share the following day, directly affecting investor confidence.
- Regulatory Review Change: On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 BLA on a standard review timeline instead of the accelerated review, leading to a 24.45% stock price plunge to $1.73 per share, further exacerbating investor losses.
- False Statements Allegations: The class action lawsuit alleges that Inovio failed to disclose critical negative information throughout the class period, including manufacturing deficiencies and insufficient information for accelerated approval, indicating that the company's positive statements about regulatory and commercial prospects lacked a reasonable basis, harming investor interests.
See More
Inovio Pharmaceuticals Securities Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, that they must apply to be lead plaintiff by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of its INO-3107 Biologics License Application, resulting in investor losses once the truth was revealed.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its successful track record and resources in this field.
- Investor Guidance: Investors are advised to select law firms with proven success records to ensure effective legal representation in class actions, avoiding those that merely act as intermediaries without substantial litigation experience.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging investors to file lead plaintiff motions by the specified deadlines to protect their rights.
- BlackRock TCP Details: The lawsuit alleges that from November 2024 to January 2026, BlackRock failed to timely and appropriately value its investments, leading to understated unrealized losses and an overstated net asset value, which misled investors about the company's financial health.
- Oracle Lawsuit Impact: The class action against Oracle, covering June to December 2025, claims that its AI infrastructure strategy would result in significant capital expenditure increases without corresponding revenue growth, posing serious risks to the company's debt and credit rating.
- Paysafe and Inovio Situations: Paysafe's lawsuit highlights its significant exposure to a high-risk client, potentially harming revenue growth, while Inovio faces challenges in submitting a critical FDA application due to manufacturing deficiencies, jeopardizing its market prospects.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026.
- False Statements Allegation: The complaint alleges that Inovio made false and misleading statements regarding manufacturing deficiencies in its CELLECTRA device and indicated that filing for the INO-3107 BLA by 2H 2024 was unlikely, which has led to significant investor losses.
- FDA Review Issues: Inovio failed to provide sufficient evidence supporting an FDA priority review or accelerated approval for its BLA, rendering its public statements throughout the class period false and materially misleading, which negatively impacted investor confidence and stock price.
- Legal Consequences: Following the revelation of the truth about Inovio, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit for recovery, highlighting the significant legal risks that may impact the company's future operations.
See More
Faruqi & Faruqi Investigates Inovio Investor Losses
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Inovio Pharmaceuticals, focusing on investors who purchased securities between October 10, 2023, and December 26, 2025, to assess potential legal claims against the company.
- Investor Rights Reminder: The firm reminds investors that April 7, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Channels: Investors who have suffered losses are encouraged to contact Faruqi & Faruqi partner Josh Wilson directly, with multiple contact numbers provided for ease of consultation and discussion of legal options.
- Class Action Context: This investigation is linked to an existing federal securities class action against Inovio, indicating potential legal risks for the company that investors should closely monitor for implications on their investments.
See More
Inovio Pharmaceuticals Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose manufacturing deficiencies in its CELLECTRA device, which overstated the prospects of its INO-3107 Biologics License Application, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its expertise in this field.
- How to Participate: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel, especially since the class has not yet been certified, requiring careful consideration of legal representation.
See More
Inovio Pharmaceuticals Class Action Reminder for Investors
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that April 7, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, indicating potential investor losses.
- Financial Impact: On August 8, 2024, Inovio's second quarter financial results revealed a delay in submitting the BLA to the FDA due to manufacturing issues, causing the stock price to drop 3.1% to $8.44 per share the following day, directly affecting investor confidence.
- Regulatory Review Change: On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 BLA on a standard review timeline instead of the accelerated review, leading to a 24.45% stock price plunge to $1.73 per share, further exacerbating investor losses.
- False Statements Allegations: The class action lawsuit alleges that Inovio failed to disclose critical negative information throughout the class period, including manufacturing deficiencies and insufficient information for accelerated approval, indicating that the company's positive statements about regulatory and commercial prospects lacked a reasonable basis, harming investor interests.
See More
